The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy

GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy

October 23, 2017 • By Ben Hirschler

  • Tweet
  • Email
Print-Friendly Version / Save PDF

LONDON (Reuters)—GlaxoSmithKline has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year.

You Might Also Like
  • GlaxoSmithKline’s Shingles Vaccine Gets Approval in Canada
  • The Effect of Tofacitinib on Live Vaccine Responses
  • GSK Shuts U.S. Plant Due to Bacteria

It also secured a recommendation from U.K. cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease—a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene therapy commercially since its May 2016 approval in Europe.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The green light for GSK’s shingles shot, Shingrix, which has proved significantly better than Merck & Co’s Zostavax in clinical trials, is an important vindication of GSK’s product pipeline. The news was announced late on Friday.

GSK’s vaccine is considered one of the more pivotal products in its pipeline, with annual sales forecast to reach 1.03 billion pounds ($1.36 billion) by 2023, Thomson Reuters data shows.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Although largely expected, today’s approval is an important one for GSK – a new product with a clear best-in-class profile,” Berenberg analysts says. “We expect approval in Europe late this year.”

The U.S. Food and Drug Administration (FDA) approval comes a month after it cleared GSK’s three-in-one inhaler for chronic lung disease.

The third new product GSK expects to launch in the world’s biggest drugs market is a dual-drug regimen for HIV, on which the U.S. regulator is scheduled to give a verdict by Dec. 1.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Chief Executive Emma Walmsley, who will present third-quarter financial results on Wednesday, sees the three products as “critical” for GSK’s efforts to fill the revenue gap left by falling sales of the ageing lung drug Advair.

The FDA approved Shingrix, which is given in two doses, for adults age 50 and over. Approval had been expected after an advisory panel to the agency backed the product.

Shingrix is more effective than Zostavax, the only currently available shingles prevention vaccine, which is given as a single dose. GSK said it expects Shingrix to be “available shortly”.

Immunization Committee
The U.S. Centers for Disease Control and Prevention‘s advisory committee on immunization practices is expected to vote on a recommendation for the use of Shingrix at its meeting on Wednesday.

The outcome of that meeting may determine just how big the product becomes.

Many analysts expect the committee to recommend routine vaccination of the over-60s, as is currently the case with Zostavax, but an endorsement of use in younger people would represent commercial upside.

Older adults are most at risk of shingles, a painful, often debilitating blistering rash that results from reactivation of the varicella zoster virus that causes chickenpox and remains latent in those who have had that disease.

Shingrix contains a component from Agenus, which is entitled to royalties on future sales.

Meanwhile, Britain’s National Institute for Health and Care Excellence (NICE) said on Monday that it had approved GSK’s gene therapy Strimvelis for treating ADA-SCID—better known as “bubble boy” disease—despite its steep price tag of 594,000 euros ($698,000).

Infants with the condition need to be kept in isolation to avoid infections and the cost to the state health service can run to millions of pounds, so a one-off genetic cure can prove cost-effective even at a very high price.

Pages: 1 2 | Multi-Page

Filed Under: Conditions Tagged With: FDA approval, shingles, Shingrix, U.S. Food and Drug Administration (FDA), vaccine

You Might Also Like:
  • GlaxoSmithKline’s Shingles Vaccine Gets Approval in Canada
  • The Effect of Tofacitinib on Live Vaccine Responses
  • GSK Shuts U.S. Plant Due to Bacteria
  • Shingles Vaccination Not at Goal Levels for U.S. Seniors

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)